Clinical Trials Browser

Phase 2 × durvalumab × Gastrointestinal × Clear all

NCT02888743 2026-03-18

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2 Active not recruiting

110 enrolled 21 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04301778 2026-03-13

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Phase 2 Completed

5 enrolled 13 charts

Gastrointestinal

Cholangiocarcinoma

NCT06728410 2026-03-09

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT06859684 2026-03-09

HAIC-quad

Phase 2 Recruiting

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT04705818 2026-03-06

CAIRE

Phase 2 Completed

GastrointestinalSarcoma

Tertiary Lymphoid Structures, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT05063565 2026-03-02

ROWAN

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT04945720 2026-02-25

Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma

Phase 2 Completed

30 enrolled 9 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

39 enrolled 8 charts

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04522544 2026-02-18

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Phase 2 Active not recruiting

433 enrolled 26 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03937830 2026-02-05

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05620628 2026-01-21

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT06040099 2026-01-20

EMERALD-Y90

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06855225 2026-01-14

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Liver Neoplasms

NCT07036380 2026-01-09

TACTIC

Phase 2 Recruiting

Gastrointestinal

Advanced Biliary Tract Carcinoma

NCT06526104 2026-01-06

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT07081633 2025-12-30

TREMENDOUS-2

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06880523 2025-12-18

SLIDE-HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05733598 2025-12-15

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04238637 2025-12-05

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT06440993 2025-12-01

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT03777813 2025-11-18

ARION

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT06994299 2025-11-18

PRISM

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT06698250 2025-11-06

ZENOBIA

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04940286 2025-10-08

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06999694 2025-09-10

Proton-STRIDE

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05194293 2025-09-04

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03638141 2025-08-17

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Phase 2 Completed

21 enrolled 12 charts

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07122089 2025-08-14

IOSPHERE

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06441747 2025-07-29

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT06290505 2025-07-23

PALEO

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT05451043 2025-06-26

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT02678182 2025-06-10

PLATFORM

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma of the Oesophagus

NCT04817826 2025-06-10

INFINITY

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms, Microsatellite Instability

NCT07012798 2025-06-10

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05712356 2025-06-06

BOLSTER

Phase 2 Active not recruiting

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT06999707 2025-06-05

Photon-STRIDE

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Phase 2 Active not recruiting

GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05239169 2025-05-01

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT03653052 2025-04-24

CALIBRATION

Phase 2 Active not recruiting

Gastrointestinal

Esophageal Neoplasms

NCT06045975 2025-04-02

DUMELEP

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03899428 2025-03-24

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05655949 2025-03-10

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT05222971 2025-01-28

OPTIMUM

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT06274879 2025-01-09

Ablatio

Phase 2 Not yet recruiting

Gastrointestinal

Bile Duct Neoplasms

NCT06094140 2024-12-03

NEO-IMPACT

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05027425 2024-11-22

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Phase 2 Active not recruiting

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal